On May 18, 2023, the FDA’s vaccine committee met to vote on whether Pfizer’s new RSV vaccine is “safe” and “effective.” Ahead of that meeting, ICAN, through its attorneys, wrote a letter to the FDA committee members to warn about numerous serious issues evident from its clinical trial, including the low efficacy, significant adverse events, […]
Today’s Legislative Call to Action: FDA Ethics Act of 2022
HB 8828 FDA Ethics Act of 2022 US Congress 117th Congress About HB-8828 To address potential conflicts of interest among entities serving as Food and Drug Administration contractors, and for other purposes. Conflicts of interest are ok as long as they are disclosed. No prohibition against licensing agreements with […]